Bank Julius Baer & Co
TEVA icon

Bank Julius Baer & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Bank Julius Baer & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,500
Closed -$124K – 791
2021
Q4 		$124K Hold
15,500
– – ﹤0.01% 587
2021
Q3 		$151K Buy
15,500
+45
+0.3% +$421 ﹤0.01% 586
2021
Q2 		$153K Sell
15,455
-45
-0.3% -$476 ﹤0.01% 601
2021
Q1 		$179K Sell
15,500
-3,464
-18% -$39.7K ﹤0.01% 554
2020
Q4 		$183K Buy
18,964
+2,964
+19% +$28.4K ﹤0.01% 591
2020
Q3 		$144K Buy
16,000
+4,000
+33% +$42.3K ﹤0.01% 541
2020
Q2 		$148K Buy
+12,000
New +$136K ﹤0.01% 496

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Bank Julius Baer & Co's TEVA Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 15,500 shares — an estimated $124K sold.

Bank Julius Baer & Co first reported a position in TEVA in Q2 2020 and held it in 7 quarters. The position peaked at $183K in Q4 2020. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 15,500 Teva Pharmaceuticals shares in Q1 2022, an estimated $124K.
  • Bank Julius Baer & Co first reported a position in Teva Pharmaceuticals in Q2 2020 and held it in 7 quarters.
  • Bank Julius Baer & Co's Teva Pharmaceuticals position peaked at $183K in Q4 2020.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.